Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label study of telisotuzumab vedotin in previously treated c-Met-positive non-small cell lung cancer
CTR20190277Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Sep 2019
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of telisotuzumab vedotin in non-small cell lung cancer (NSCLC), sponsored by AbbVie Inc.. Started Sep 2019; status: completed.
02
Drugs
telisotuzumab vedotin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20190277.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20190277.